title: Angiotensin-converting enzyme inhibition in the treatment of renal transplant erythrocytosis. Clinical experience and observation of mechanism.
abstract: Recent observations indicate that angiotensin-converting enzyme (ACE) inhibition corrects renal transplant erythrocytosis (RTE). The mechanism for this association is not known. We examined the effect of ACE inhibition on hematocrit, erythropoietin (EPO), and renin substrate. ACE inhibition has been reported to suppress renin substrate, which is known to stimulate EPO and erythropoiesis. In 15 patients with RTE, hematocrit dropped from 52.8 +/- 0.6 (SEM) to 45.8 +/- 1.4% after 8 weeks of treatment with Enalapril, 2.5-20 mg/day. Serum EPO (normal range: 9-30 mU/ml) was high in one, normal in seven, and low in seven patients. ACE inhibition reduced EPO in patients with initial high or normal levels but induced no change in patients with initial low levels. ACE inhibition had no significant effect on renin substrate. In one patient who rejected his first graft, erythrocytosis recurred following a second, successful transplant. Treatment was discontinued because of cough in two patients and symptomatic drop in blood pressure in one patient. We conclude RTE is not caused by hypererythropoietinemia. In patients with normal circulating EPO, erythrocytosis may result from an increase sensitivity to EPO, and ACE inhibition lowered hematocrit by further reduction of this hormone. However, the finding of erythrocytosis in half our patients with suppressed EPO, suggests the participation of non-EPO-mediated mechanism(s). The recurrence of RTE in a patient after a second transplant raises the additional possibility of patient-specific factors in the pathogenesis of this disorder. In contrast to other reports, we documented side-effects (cough, hypotension) in three (20%) of our patients. Our clinical experience, coupled with prior reports of spontaneous resolution of RTE in some patients, suggests that intermittent courses of ACE-inhibition may be the optimal strategy in the use of this form of therapy for RTE.
authors.affiliation: Department of Medicine, UCLA Medical Center, USA.
authors.forename: G M
authors.initials: GM
authors.lastname: Danovitch
authors.forename: N J
authors.initials: NJ
authors.lastname: Jamgotchian
authors.forename: P H
authors.initials: PH
authors.lastname: Eggena
authors.forename: W
authors.initials: W
authors.lastname: Paul
authors.forename: J D
authors.initials: JD
authors.lastname: Barrett
authors.forename: A
authors.initials: A
authors.lastname: Wilkinson
authors.forename: D B
authors.initials: DB
authors.lastname: Lee
mesh_terms: D000328:Adult; D004656:Enalapril / Q000009:adverse effects / Q000627:therapeutic use*; D004921:Erythropoietin / Q000097:blood; D005260:Female; D006400:Hematocrit; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011086:Polycythemia / Q000188:drug therapy*; D012008:Recurrence; D014184:Transplantation, Homologous
chemical_list: D004921:Erythropoietin; D004656:Enalapril